PharmiWeb.com - Global Pharma News & Resources
02-Nov-2022

Global Gastrointestinal Therapeutics Strategic Business Report 2022: Market to Reach $84.4 Billion by 2027 - Crohn's Disease is Expected to Account for $16.3 Billion - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Gastrointestinal Therapeutics: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.


Global Gastrointestinal Therapeutics Market to Reach $84.4 Billion by 2027

The global market for Gastrointestinal Therapeutics estimated at US$61.2 Billion in the year 2020, is projected to reach a revised size of US$84.4 Billion by 2027, growing at a CAGR of 4.7% over the analysis period 2020-2027.

Crohn`s Disease, one of the segments analyzed in the report, is projected to record a 4.6% CAGR and reach US$16.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Ulcerative Colitis segment is readjusted to a revised 4.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $16.5 Billion, While China is Forecast to Grow at 7.5% CAGR

The Gastrointestinal Therapeutics market in the U.S. is estimated at US$16.5 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$17.5 Billion by the year 2027 trailing a CAGR of 7.5% over the analysis period 2020 to 2027.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.7% and 3.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$11.4 Billion by the year 2027.

GERD Segment to Record 5.1% CAGR

In the global GERD segment, USA, Canada, Japan, China and Europe will drive the 5.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$5.1 Billion in the year 2020 will reach a projected size of US$7.1 Billion by the close of the analysis period.

China will remain among the fastest growing in this cluster of regional markets. Latin America will expand at a 5.5% CAGR through the analysis period.

What's New for 2022?

  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and a Research Platform
  • Complimentary updates for one year

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Influencer Market Insights
  • World Market Trajectories
  • Gastrointestinal Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS

  • AbbVie, Inc.
  • Alfa Wassermann, Inc.
  • Allergan PLC
  • Amgen, Inc.
  • Anterogen Co., Ltd.
  • Ardelyx, Inc.
  • Astellas Pharma, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Biogen, Inc.
  • Celgene Corporation
  • Cosmo Pharmaceuticals NV
  • Drais Pharmaceuticals, Inc.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Enlivex Therapeutics ltd.
  • F. Hoffmann-La Roche AG
  • Ferring Pharmaceuticals, Inc.
  • FF Pharma
  • Galapagos NV
  • Gilead Sciences, Inc.
  • GlaxoSmithKline, Inc.
  • Hutchison MediPharma Limited
  • Immune Pharmaceuticals, Inc.
  • InDex Pharmaceuticals Holding AB
  • Ironwood Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Kissei Pharmaceutical Co., Ltd.
  • Kyowa Hakko Kirin Co., Ltd.
  • Lexicon Pharmaceuticals, Inc.
  • Lipid Therapeutics GmbH
  • Meda AB
  • Merck & Co., Inc.
  • Mesoblast Ltd.
  • Mitsubishi Tanabe Pharma Corporation
  • Mochida Pharmaceutical Co., Ltd.
  • Morphotek, Inc.
  • Neovacs S.A.
  • Nestle SA
  • Norgine BV
  • Novartis AG
  • Pfizer, Inc.
  • Procter & Gamble Company, The
  • Qu Biologics Inc.
  • RedHill Biopharma Ltd.
  • Sterna Biologicals GmbH & Co. KG
  • Synthetic Biologics, Inc.
  • Takeda Pharmaceutical Co., Ltd.
  • TiGenix NV
  • Tillotts Pharma AG
  • TopiVert Ltd.
  • UCB SA

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. REGIONAL MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/hhdnls


Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 02-Nov-2022